Skip to main content


Figure 6 | Molecular Autism

Figure 6

From: Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model

Figure 6

Metabolites and pathways associated with suramin treatment in the Fragile X model. The top 30 most discriminating metabolites and their biochemical pathways ranked by variable importance in projection (VIP) scores. See Additional file 1: Table S3 for a complete list of the top 58 discriminating metabolites. VIP scores ≥1.5 were considered statistically significant. Age 25 weeks, N = 9-11 per group.

Back to article page